筋骨痛消丸靶向Src通路改善骨关节炎的机制探讨OA

Objective:To study the mechanism of action of Jinggu Tongxiao Wan(筋骨痛消丸)in ameliorating osteoarthritis.Methods:Human chondrosarcoma cells line SW1353 were induced by lipopolysaccharide(LPS)and then cultured in high,medium and low concentrations of Jinggu Tongxiao Wan drug-containing serum as well as PP2 chemical inhibitors,respectively.Cell viability and its related markers,including VEGF level and expression of SOX9 and Src proteins were detected by CCK-8,ELISA and immunofluorescence staining,respectively.Results:LPS induction inhibited SW1353 cells viability,promoted VEGF secretion,upregulated Src expression,and downregulated SOX9 expression.In contrast,intervention with the drug-containing serum of Jinggu Tongxiao Wan and PP2 enhanced cell viability suppressed VEGF secretion,reduced Src expression,and correspondingly increased SOX9 expression.Moreover,with the increase in the concentration of the drug-containing serum,cell viability was enhanced,VEGF secretion were decreased,Src expression was increased first and then was decreased,and SOX9 expression was elevated.Conclusion:The drug-containing serum of Jinggu Tongxiao Wan inhibits the angiogenesis of blood vessels by suppressing VEGF,thereby blocking the Src signaling pathway and promoting the expression of SOX9,ultimately suppressing osteoarthritis.